Primers A and B flank the anterior part of exon 9 where mutation 1226 is located. The posterior part of exon 9 (where mutation 1366 is located), exon 10 and exon 11 are flanked by primers C and D. Poly-A mRNA was isolated from cultured fibroblasts using the Micro-FastTrack™ mRNA Isolation Kit (Invitrogen Corporation). The cDNA of the glucocerebrosidase gene was synthesized by reversed transcription of fibroblast poly-A mRNAs using the cDNA Cycle™ Kit (Invitrogen Corporation), and amplified by the PCR method as previously described (14) . The nucleotide sequences of the primers for the first strand cDNA synthesis (primer D) and PCR amplification (primers D and E) are shown in Table 1 . These primers are designed to cover the full length cDNA of glucocerebrosidase (14) . Sequence analysis was performed using the dideoxynucleotide chain termination method by Sanger et al. (15) and the fmol™DNA Sequencing System (Promega Corporation, Madison, WI). The PCR mismatch method and Xhol RFLP analysis (9) were used to detect mutation 1226. For mutation 1366, genomic DNA amplified by the PCR method using primers C and F (Table 1 ) was subjected to Ncol RFLP analysis.
Xhol RFLP analysis showed that mutation 1226 is present in the heterozygous form in the patient. This finding was confirmed by sequence analysis. The presence of an A -G transition in the heterozygous form was noted at cDNA nt 1226. In view of this finding and the report that mutation 1226 is present only in type 1 Gaucher disease (16), the patient was diagnosed as having the non-neuronopathic type 1 form.
The mutation in the other Gaucher allele was also identified during sequence analysis. As shown in Fig. 1, there To whom correspondence should be addressed The nucleotide position of glucocerebrosidase genomic DNA is numbered according Horowitz et al. (13) . b The nucleotide position of glucocerebrosidase cDNA is numbered according to Sorge et al. (22) where A of the first ATG initiation codon is position no. 1. c Primers C and F (instead of C and D) were used f or the PCR amplification and Ncol RFLP analysis of mutation 1366 because these primers generate smaller DNA fragments that are easier for identification.
endonuclease cleavage sites showed that the mutation has created a new Ncol site. The presence of mutation 1366 was subsequently confirmed by Ncol RFLP analysis. As shown in Fig. 2 , two bands of 226 and 592 b.p. were found in the control because of a naturally occurring Ncol cleavage site at genomic nt 6146. In the patient, the 1366 mutation creates a second Ncol site which results in the cleavage of the band of 226 b.p. to two bands of 61 and 165 b.p. Since both the 226 b.p. and 165 b.p. bands are present (lane 2, Fig. 2 ), it demonstrates that mutation 1366 is present in the heterozygous form.
In order to rule out the possibility of multiple point mutations that may be present among some Gaucher patients (17,18), we performed sequence analysis of the full length cDNA of the glucocerebrosidase gene. We detected the presence of a heterozygous silent mutation at cDNA nt 84 (G-T transversion) at the degenerate position of the codon for glycine, and a heterozygous base substitution at cDNA nucleotide position 1601 (A -G transition) that results in 495 His-495 Arg. The later finding is of interest because it was previously reported that this may be a cloning artifact (19) or a neutral mutation among normal individuals (20) . In this present study, we performed direct sequence analysis on PCR-amplified glucocerebrosidase cDNA synthesized by reverse transcription. This procedure by-passed the gene cloning step and eliminated the possibility of error arising from gene cloning. The possibility of error resulting from Taq polymerase is also unlikely since consistent reproducible findings were noted using cDNA samples that were PCR-amplified in separate experiments. It will be interesting to screen for the presence of this base substitution at cDNA 1601 among normal individuals and Gaucher patients to confirm this observation and estimate its frequency in the population.
Sequence analysis of the rest of the glucocerebrosidase cDNA showed that the DNA base sequences are identical to that of the published sequences from normal individuals (13) .
The 1226 mutation is the most common mutation in Gaucher disease (5) . It was postulated that homozygous 1226 mutation will result in mild clinical presentation, delayed onset of symptoms and good prognosis (5, 16, 21) . However, when it is present in the heterozygous form with either the 1448 mutation, exon 2 insertion mutation or intron 2 splicing mutation, the clinical severity scores assigned to the patients are considerably higher (5) . The clinical course of Gaucher disease in our patient with the 1226/1366 genotype so far has been a mild one. The splenectomy performed ten years ago on the patient has apparently reversed the hematological complications and there has been no history of bone pain, bruising and no evidence of hepatic or neurological involvement. As she is asymptomatic, Figure 2 . Ncol RFLP analysis of mutation 1366. Conditions for the PCR amplification, endonuclease digest and PAGE were as previously described (14) . further investigations such as MRI of the bones, liver biopsy or bone marrow examination have not been done. It will be interesting to monitor the clinical course of our patient and observe the effect of this 1226/1366 genotype on the clinical expressivity of Gaucher disease.
